With 79354.0 shares changed hands, the volume of the stock remained lighter than its average volume of 0.13 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $4.07 whereas the lowest price it dropped to was $3.904. The 52-week range on CING shows that it touched its highest point at $9.69 and its lowest point at $3.02 during that stretch. It currently has a 1-year price target of $26.67. Beta for the stock currently stands at -0.78.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CING was down-trending over the past week, with a drop of -4.77%, but this was down by -22.97% over a month. Three-month performance surged to 1.79% while six-month performance fell -3.16%. The stock lost -19.07% in the past year, while it has lost -59.62% so far this year. A look at the trailing 12-month EPS for CING yields -5.77 with Next year EPS estimates of -2.60. For the next quarter, that number is -0.88. This implies an EPS growth rate of 63.55% for this year and 30.06% for next year. EPS is expected to grow by 52.84% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 40.00%.
Float and Shares Shorts:
At present, 5.41 million CING shares are outstanding with a float of 5.23 million shares on hand for trading. On 2025-08-15, short shares totaled 0.2 million, which was 361.0 higher than short shares on 1752537600. In addition to Mr. John A. Roberts M.B.A. as the firm’s Executive Chairman, Ms. Jennifer L. Callahan CPA serves as its Interim CEO, Senior VP, CFO & Secretary.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-06-30, CING reported revenue of $0.0 and operating income of -$4649939.0. The EBITDA in the recently reported quarter was -$4502950.0 and diluted EPS was -$1.09.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With CING analysts setting a high price target of 62.0 and a low target of 8.0, the average target price over the next 12 months is 27.71333. Based on these targets, CING could surge 1453.88% to reach the target high and rise by 100.5% to reach the target low. Reaching the average price target will result in a growth of 594.57% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$7.27197 being high and -$13.36558 being low. For CING, this leads to a yearly average estimate of -$9.435. The surprise factor in the prior quarter was -$0.98. Based on analyst estimates, the high estimate for the next quarter is -$0.44 and the low estimate is -$0.82. The average estimate for the next quarter is thus -$0.65.
